Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE) is a research paper published in European Urology Focus (2023). On theSindex it has a DataRank of 0.587. It has been cited 49 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.587
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: U10CA180794
National Cancer Institute
Grant: U10CA180820
National Cancer Institute
Grant: UG1CA180830
National Cancer Institute
Grant: UG1CA189854
National Cancer Institute
Grant: UG1CA233180
National Cancer Institute
Grant: UG1CA233196
National Cancer Institute
Grant: UG1CA233290
National Cancer Institute
Grant: UG1CA233373
NCI NIH HHS
Grant: P30 CA086862
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: U10 CA180830
National Institutes of Health
MeSH Terms